Skip to main content

Satellos Bioscience Inc(MSCL-T)
TSX

Today's Change
Real-Time Last Update
Day Low9.75
Day High10.18
Open:9.93
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

Top Stories: Satellos Bioscience Inc

Select a category then submit the form to load news
Baystreet
Stocks in play: Satellos Bioscience Inc.
GlobeNewswire
Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference
Baystreet
Stocks in play: Satellos Bioscience Inc.
Business Wire
Satellos to Participate in Upcoming Investor Conferences
Baystreet
Stocks in play: Satellos Bioscience Inc.
Business Wire
Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Baystreet
Stocks in play: Satellos Bioscience Inc.
Business Wire
Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs
Baystreet
Stocks in play: Satellos Bioscience Inc.
Baystreet
Stocks in play: Satellos Bioscience Inc.
Business Wire
Satellos Announces Publication in Nature Communications Supporting its Novel Treatment Approach for Duchenne Muscular Dystrophy
Business Wire
Satellos Reports Third Quarter 2025 Results and Announces Appointment of Mark Nawacki to Board of Directors
Business Wire
Satellos to Participate in November Investor Conferences
Baystreet
Stocks in play: Satellos Bioscience Inc.
Business Wire
Satellos Announces First Adult Patient Dosed in LT-001, an Open-Label, Long-Term Follow-Up Study of SAT-3247 in Duchenne Muscular Dystrophy
Business Wire
Satellos Announces New Data Further Demonstrating Safety, Tolerability, and Functional Impact of SAT-3247 in First-in-Human Trial of Adults with Duchenne Muscular Dystrophy
Business Wire
Satellos to Present SAT-3247 Phase 1 Clinical Data in Late-Breaking Poster Session at the 2025 World Muscle Society Congress
Baystreet
Stocks in play: Satellos Bioscience Inc.
Business Wire
Satellos Announces IND Submission to the U.S. FDA and Global Regulatory Filings to Advance a Phase 2 Clinical Trial of SAT-3247 in Children with Duchenne Muscular Dystrophy
Business Wire
Satellos to Participate in Four September Institutional and Retail Investor Conferences
Baystreet
Stocks in play: Satellos Bioscience Inc.
Business Wire
Satellos Reports Second Quarter 2025 Results and Highlights Upcoming Clinical Milestones
Baystreet
Stocks in play: Satellos Bioscience Inc.
Business Wire
Satellos to Present at Canaccord Genuity’s 45th Annual Growth Conference
Baystreet
Stocks in play: Satellos Bioscience Inc.
Business Wire
Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer
Business Wire
Satellos Bioscience to Participate in PPMD’s Annual Conference in Las Vegas
Baystreet
Stocks in play: Satellos Bioscience Inc.
Newsfile
Bloom Burton & Co. Inc. Announces Exercise of Satellos Bioscience Inc. Warrants
Business Wire
Satellos Reports First Quarter 2025 Results and Highlights Recent Company Progress
Business Wire
Satellos to Present at Bloom Burton & Co. Healthcare Investor Conference
Business Wire
Satellos to Participate in Two April Investor Conferences

Profile

Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.